| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Clinical Pharmacology and Therapeutics Unit, Heidelberg, Victoria, Australia2 Experimental Oncology Unit, University of Newcastle, Callaghan, New South Wales, Australia and3 Department of Nephrology, Austin Health, Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia
Requests for reprints: Albert G. Frauman, Clinical Pharmacology and Therapeutics Unit, Austin Health, Department of Medicine, University of Melbourne, Level 5, Lance Townsend Building, Studley Road, Heidelberg, Victoria, Australia 3084. Phone: 61-3-9496-3415; Fax: 61-3-9459-3510. E-mail: albertf{at}unimelb.edu.au
Objective: CD151 is the first member of the tetraspanin family to be associated as a promoter of human tumor metastasis. However, its biological function and expression phenotype among different tumors has not been well investigated.
Method: Tissue specimens from 76 primary prostate cancers and 30 benign prostate hyperplasia (BPH) controls were obtained from the Department of Anatomical Pathology at the Austin and Repatriation Medical Centre (now Austin Health) from 1984 to 1993. We used quantitative immunohistochemical analysis to measure CD151 protein expression. Analyses of differences among BPH and prostate cancer groups were done with one-way ANOVA and Newman-Keuls test. The Kaplan-Meier method and the log-rank test were used to estimate the overall survival.
Results: CD151 expression was found to be significantly higher in prostate cancer specimens compared with BPH specimens (P < 0.001). Poorly differentiated cancers expressed the strongest staining, whereas well-differentiated cancers expressed the weakest staining for CD151 (P < 0.001). The overall survival rate for cases in which CD151 expression was reduced was significantly higher than for cases in which CD151 expression was increased (P = 0.039) especially in well and moderately differentiated cancers (P = 0.014). This effect was independent of the patients' age or preoperative prostate-specific antigen values and superior in the predictive ability of the Gleason score.
Conclusions: CD151 has an increasing expression pattern in prostate cancer progression, and higher levels of CD151 are associated with poorer prognosis. CD151 had better predicting value for the clinical outcome of prostate cancer patients than does the traditional histologic grading method (Gleason grading).
This article has been cited by other articles:
|
|
 |
|
  J. L. Johnson, N. Winterwood, K. A. DeMali, and C. S. Stipp Tetraspanin CD151 regulates RhoA activation and the dynamic stability of carcinoma cell-cell contacts J. Cell Sci., July 1, 2009; 122(13): 2263 - 2273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sadej, H. Romanska, G. Baldwin, K. Gkirtzimanaki, V. Novitskaya, A. D. Filer, Z. Krcova, R. Kusinska, J. Ehrmann, C. D. Buckley, et al. CD151 Regulates Tumorigenesis by Modulating the Communication between Tumor Cells and Endothelium Mol. Cancer Res., June 1, 2009; 7(6): 787 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-W. Chien, S.-C. Lin, Y.-Y. Lai, B.-W. Lin, S.-C. Lin, J.-C. Lee, and S.-J. Tsai Regulation of CD151 by Hypoxia Controls Cell Adhesion and Metastasis in Colorectal Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8043 - 8051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. H. Yang, A. L. Richardson, M. I. Torres-Arzayus, P. Zhou, C. Sharma, A. R. Kazarov, M. M. Andzelm, J. L. Strominger, M. Brown, and M. E. Hemler CD151 Accelerates Breast Cancer by Regulating {alpha}6 Integrin Function, Signaling, and Molecular Organization Cancer Res., May 1, 2008; 68(9): 3204 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-K. Hong, Y.-J. Jin, H.-J. Byun, D.-I. Jeoung, Y.-M. Kim, and H. Lee Homophilic Interactions of Tetraspanin CD151 Up-regulate Motility and Matrix Metalloproteinase-9 Expression of Human Melanoma Cells through Adhesion-dependent c-Jun Activation Signaling Pathways J. Biol. Chem., August 25, 2006; 281(34): 24279 - 24292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Winterwood, A. Varzavand, M. N. Meland, L. K. Ashman, and C. S. Stipp A Critical Role for Tetraspanin CD151 in {alpha}3beta1 and {alpha}6beta4 Integrin-dependent Tumor Cell Functions on Laminin-5 Mol. Biol. Cell, June 1, 2006; 17(6): 2707 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Le Naour, M. Andre, C. Greco, M. Billard, B. Sordat, J.-F. Emile, F. Lanza, C. Boucheix, and E. Rubinstein Profiling of the Tetraspanin Web of Human Colon Cancer Cells Mol. Cell. Proteomics, May 1, 2006; 5(5): 845 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bredel, C. Bredel, D. Juric, G. R. Harsh, H. Vogel, L. D. Recht, and B. I. Sikic Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas Cancer Res., October 1, 2005; 65(19): 8679 - 8689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Low Grade Primary Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 553 - 553. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
